b**a
发帖数: 1118 | 1 【 以下文字转载自 MoneyFriends 俱乐部 】
发信人: buaa (ming), 信区: MoneyFriends
标 题: A very reasonable post from Yahoo about HGSI
发信站: BBS 未名空间站 (Wed Apr 25 03:01:09 2012, 美东)
This is all about Darapladib. HGSI won't budge and should not until they
know the full potential of Darapladib. Shortie wants your stock because they
know where this is heading. GSK is not buying us for Benlysta at this point
. They are going to have to pay big time dollars to HGSI to get Darapladib
to market. Benlysta sales are growing, 21% over last quarter. This is GSK's
chance to buy HGSI cheap or lose billions of revenue on future sales of
Darapladib.
And from today's conference call, Quote:
Clearly, if it is successful, darapladib targets a large and lucrative
market, and we have attractive economics on this drug, which includes a 10%
royalty on worldwide sales and additionally, a 20% profit sharing co-
promotion arrangement or option on sales in North America and Europe. If
successful approximately one-third of the value of this drug would flow to
Human Genome Sciences shareholders.
Now GSK is investing very heavily to develop darapladib, and the combined
Phase 3 clinical program is one of the largest ever conducted to evaluate
any cardiovascular medication. GSK is running about 28,000 patients in two
large Phase 3 trials at the current time. Each of these studies is event
driven and will end when 1,500 patients have a major adverse cardiovascular
event, which is typically a heart attack or stroke.
End quote. |
|
